Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2)

Oncogene

Volumn 28, Issue 45, 2009, Pages 3983-3996

  Arlt, A ^a   Bauer, I ^a   Schafmayer, C ^a   Tepel, J ^a   Müerköster, S Sebens ^a   Brosch, M ^a   Roder C ^a   Kalthoff, H ^a   Hampe, J ^a   Moyer, M P ^b   Folsch U R ^a   Schafer H ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UKSH Campus Kiel ^*  (United States)

Author keywords

Gene transcription; Oxidative stress; Regulated proteolysis; Tumorigenesis; Ubiquitination

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEIN ALPHA 5; PROTEIN S5A; PROTEIN SUBUNIT; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; COLON CANCER; COLON CARCINOGENESIS; COLON MUCOSA; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

BLOTTING, WESTERN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 70449674487     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.264     Document Type: Article

References (68)

1. Adams J. (2004). The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5: 417-421.
2. Almond JB, Cohen GM. (2003). The proteasome: a novel target for cancer chemotherapy. Leukemia 16: 433-443.
3. Arlt A, Kruse ML, Breitenbroich M, Gehrz A, Koc B, Minkenberg J et al. (2003). The early response gene IEX-1 attenuates NFeB activation in 293 cells, a possible counterregulatory process leading to enhanced cell death. Oncogene 22: 3343-3350.
4. Arlt A, Minkenberg J, Kruse ML, Grohmann F, Folsch UR, Schafer H. (2007). Immediate early gene-X1 interferes with 26 S proteasome activity by attenuating expression of the 19 S proteasomal components S5a/Rpn10 and S1/Rpn2. Biochem J 402: 367-375.
5. Baumeister W, Walz J, Zuhl F, Seemuller E. (1998). The proteasome: paradigm of a self-compartmentalizing protease. Cell 92: 367-380.
6. Chen L, Madura K. (2005). Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res 65: 5599-5606.
7. Chen W, Hu XT, Shi QL, Zhang FB, He C. (2009). Knockdown of the novel proteasome subunit Adrm1 located on the 20q13 amplicon inhibits colorectal cancer cell migration, survival and tumorigeni-city. Oncol Rep 21: 531-537.
8. Cho HY, Reddy SP, Debiase A, Yamamoto M, Kleeberger SR. (2005). Gene expression profiling of NRF2-mediated protection against oxidative injury. Free Radic Biol Med 38: 325-343. (Pubitemid 40081112)
9. Conaway RC, Brower CS, Conaway JW. (2002). Emerging roles of ubiquitin in transcription regulation. Science 296: 1254-1258.
10. Coux O, Tanaka K, Goldberg AL. (1996). Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65: 801-847. (Pubitemid 26255262)
11. Dahlmann B. (2007). Role of proteasomes in disease. BMC Biochem 8(Suppl 1): S3.
12. Devoy A, Soane T, Welchman R, Mayer RJ. (2005). The ubiquitin-proteasome system and cancer. Essays Biochem 41: 187-203.
13. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. (2003). TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22: 3842-3852.
14. Elsasser S, Chandler-Militello D, Muller B, Hanna J, Finley D. (2004). Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome. J Biol Chem 279: 26817-26822.
15. Glickman MH, Ciechanover A. (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2: 373-428.
16. Goldberg AL. (2007). Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 35: 12-17.
17. Goldberg AL. (2003). Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899.
18. Goy A, Hart S, Pro B, McLaughlin P, Younes A, Dang N et al. (2003). Report of a phase II study of proteasome inhibitor bortezomib (VELCADE) in patients with relapsed or refractory indolent or aggressive lymphomas. Blood 102: 180a.
19. Gudmundsdottir K, Lord CJ, Ashworth A. (2007). The proteasome is involved in determining differential utilization of double-strand break repair pathways. Oncogene 26: 7601-7606.
20. Hayes JD, McMahon M. (2009). NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34: 176-188.
21. Hershko A, Ciechanover A. (1998). The ubiquitin system. Annu Rev Biochem 67: 425-479.
22. Hu R, Xu C, Shen G, Jain MR, Khor TO, Gopalkrishnan A et al. (2006). Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Cancer Lett 243: 170-192.
23. Huang HC, Nguyen T, Pickett CB. (2002). Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem 277: 42769-42774.
24. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y et al. (2000). Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 275: 16023-16029.
25. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD et al. (1999). Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76-86.
26. Karin M, Cao Y, Greten FR, Li ZW. (2002). NF-kB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2: 301-310.
27. Kang Y, Chen X, Lary JW, Cole JL, Walters KJ. (2007). Defining how ubiquitin receptors hHR23a and S5a bind polyubiquitin. J Mol Biol 369: 168-176.
28. Kepa JK, Ross D. (2003). Differential expression of the antioxidant response element within the hNQO1 promoter in NSCLC versus SCLC. Biochem Biophys Res Commun 311: 446-453.
29. Khor TO, Huang MT, Kwon KH, Chan JY, Reddy BS, Kong AN. (2006). Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 66: 11580-11584.
30. Kwak MK, Kensler TW. (2006). Induction of 26S proteasome subunit PSMB5 by the bifunctional inducer 3-methylcholanthrene through the Nrf2-ARE, but not the AhR/Arnt-XRE, pathway. Biochem Biophys Res Commun 345: 1350-1357.
31. Kwak MK, Wakabayashi N, Greenlaw JL, Yamamoto M, Kensler TW. (2003). Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signalling pathway. Mol Cell Biol 23: 8786-8794.
32. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. (2008). Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262-270.
33. Leggett DS, Hanna J, Borodovsky A, Crosas B, Schmidt M, Baker RT et al. (2002). Multiple associated proteins regulate proteasome structure and function. Mol Cell 10: 495-507.
34. Liu GH, Qu J, Shen X. (2008). NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochim Biophys Acta 1783: 713-727.
35. Liu CW, Li X, Thompson D, Wooding K, Chang TL, Tang Z et al. (2006). ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome. Mol Cell 24: 39-50.
36. London MK, Keck BI, Ramos PC, Dohmen RJ. (2004). Regulatory mechanisms controlling biogenesis of ubiquitin and the proteasome. FEBS Lett 567: 259-264.
37. Mani A, Gelmann EP. (2005). The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23: 4776-4789.
38. McBride WH, Iwamoto KS, Syljuasen R, Pervan M, Pajonk F. (2003). The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene 22: 5755-5773.
39. Moyer MP, Manzano LA, Merriman RL, Stauffer JS, Tanzer LR. (1996). NCM460, a normal human colon mucosal epithelial cell line. in vitro Cell Dev Biol Anim 32: 315-317.
40. Murata S, Yashiroda H, Tanaka K. (2009). Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol 10: 104-115.
41. Nair S, Doh ST, Chan JY, Kong A-N, Cai L. (2008). Regulatory potential for concerted modulation of Nrf2-and Nfkb1-mediated gene expression in inflammation and Carcinogenesis. Br J Cancer 99: 2070-2082.
42. Nioi P, Nguyen T. (2007). A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun 362: 816-821.
43. Orlowski RZ, Dees EC. (2003). The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 5: 1-7.
44. Osburn WO, Karim B, Dolan PM, Liu G, Yamamoto M, Huso DL et al. (2007). Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int J Cancer 121: 1883-1891.
45. Osburn WO, Kensler TW. (2008). Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res 659: 31-39.
46. Pitts TM, Morrow M, Kaufman SA, Tentler JJ, Eckhardt SG. (2009). Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther 8: 342-349.
47. Ren S, Smith MJ, Louro ID, McKie-Bell P, Bani MR, Wagner M et al. (2000). The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma. Oncogene 19: 1419-1427.
48. Rho JH, Qin S, Wang JY, Roehrl MH. (2008). Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J Proteome Res 7: 2959-2972.
49. Schmidtke G, Kraft R, Kostka S, Henklein P, Frommel C, Lowe J et al. (1996). Analysis of mammalian 20S proteasome biogenesis: the maturation of beta-subunits is an ordered two-step mechanism involving autocatalysis. EMBO J 15: 6887-6898.
50. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. (2000). Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404: 770-774.
51. Sebens Muerkoster S, Rausch AV, Isberner A, Minkenberg J, Blaszczuk E, Witt M et al. (2008). The apoptosis-inducing effect of gastrin on colorectal cancer cells relates to an increased IEX-1 expression mediating NF-kappa B inhibition. Oncogene 27: 1122-1134.
52. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M et al. (2008a). Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135: 1358-1368.
53. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K et al. (2008b). Cancer related mutations in Nrf2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105: 13568-13573.
54. Singh A, Misra V, Thimmulappa RK. (2006). Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. Plos Med 3: e420.
55. Smith DM, Kafri G, Cheng Y, Ng D, Walz T, Goldberg AL. (2005). ATP binding to PAN or the 26S ATPases causes association with the 20S proteasome, gate opening, and translocation of unfolded proteins. Mol Cell 20: 687-698.
56. Sobin LH, Wittekind CH, International Union Against Cancer (UICC). (2002). TNM Classification on Malignant Tumours, 6th edn. Wiley-Liss Publications: New York.
57. Song MY, Kim EK, Moon WS, Park JW, Kim HJ, So HS et al. (2009). Sulforaphane protects against cytokine-and streptozotocin-induced b-cell damage by suppressing the NF-kB pathway. Toxicol Appl Pharmacol 235: 57-67.
58. Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM. (2004). Caspase activation inhibits proteasome function during apoptosis. Mol Cell 14: 81-93.
59. Sun Y. (2006). E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 8: 645-654.
60. Trauzold A, Wermann H, Arlt A, Schutze S, Schafer H, Oestern S et al. (2001). CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 20: 4258-4269.
61. van Tijn P, Hol EM, van Leeuwen FW, Fischer DF. (2008). The neuronal ubiquitin-proteasome system: murine models and their neurological phenotype. Prog Neurobiol 85: 176-193.
62. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI, Kobayashi A, Yamamoto M et al. (2004). Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci USA 101: 2040-2045.
63. Wang CY, Cusack Jr JC, Liu R, Baldwin Jr AS. (1999). Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417.
64. Wyke SM, Russell ST, Tisdale MJ. (2004). Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br J Cancer 91: 1742-1750.
65. Xie Y, Varshavsky A. (2001). RPN4 is a ligand, substrate, and transcriptional regulator of the 26 S proteasome: a negative feedback circuit. Proc Natl Acad Sci USA 98: 3056-3061.
66. Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J, Maher J, Motohashi H et al. (2008). Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 28: 2758-2770.
67. Yi JJ, Ehlers MD. (2007). Emerging roles for ubiquitin and protein degradation in neuronal function. Pharmacol Rev 59: 14-39.
68. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD. (2004). Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23: 2009-2015